Loading stock data…
Regeneron Pharmaceuticals, Inc. (REGN)
$827.72-15.75 (-1.87%)
Pre-Market$817.94-9.78 (-1.18%)· Last close Sep 4
Regeneron Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Regeneron Pharmaceuticals, Inc. in the Healthcare sector is trading at $827.72 with a market capitalization of $85.2B. Wall Street consensus targets $840.43 (27 analysts), implying a +1.5% move over the next 12 months. The stock is currently near its 52-week high of $859.34, remaining 13.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.29B↑ | $3.61B↓ | $3.88B↑ | $3.75B↑ | $3.68B |
| Gross Profit | $3.71B↑ | $2.94B↓ | $3.30B↑ | $3.23B↑ | $3.15B |
| Operating Income | $1.42B↑ | $744.80M↓ | $898.60M↓ | $1.11B↑ | $1.08B |
| Net Income | $1.30B↑ | $727.20M↓ | $844.60M↓ | $1.46B↑ | $1.39B |
Peer Comparison
JNJUNHPFE
Fundamentals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$80.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.12
Beta
Defensive asset. Lower volatility than the S&P 500.
0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.44%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.65%
Volume
Today's trading volume
561,170
Recent News
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...